Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional StudyHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2023Cited by 19
Therapeutic role of deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma treated with nivolumab plus ipilimumabMaki Yoshino, Toshio Takagi, Hirohito Kobayashi et al.|Japanese Journal of Clinical Oncology|2022Cited by 16
Changes in Real-World Outcomes in Patients with Metastatic Renal Cell Carcinoma from the Molecular-Targeted Therapy Era to the Immune Checkpoint Inhibitor EraHiroki Ishihara, Toshio Takagi, Yuki Nemoto et al.|Targeted Oncology|2022Cited by 10
Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumabKazutaka Nakamura, Toshio Takagi, Yudai Ishiyama et al.|International Journal of Clinical Oncology|2023Cited by 9
Impact of Body Mass Index on Outcomes in an Asian population of Advanced Renal Cell Carcinoma and Urothelial Carcinoma Treated With Immune Checkpoint InhibitorsHiroki Ishihara, Toshio Takagi, Yudai Ishiyama et al.|Clinical Genitourinary Cancer|2022Cited by 6